General Mills, Inc. vs Mesoblast Limited — how do they compare? General Mills, Inc. trades at $37.28 (market cap $20.24B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: General Mills, Inc. is far larger — about 9.2× Mesoblast Limited's market cap, and General Mills, Inc. pays a 6.43% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GIS | MESO | |
|---|---|---|
Market Cap | $20.24B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $51.11 | $20.96 |
52-Week Low | $32.17 | $12.88 |
Enterprise Value | $33.73B | $2.21B |
Dividend Yield | 6.43% | — |
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $37.26, up 1.0% with a bullish technical signal. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), but maintains strong cash flow from operations ($2.92B). Recent earnings beat expectations in Q3 2025 and Q2 2026, while analyst sentiment remains cautious with 61% hold ratings. The company continues dividend payments and focuses on cost-saving initiatives.
Investment outlook remains balanced with attractive valuation (P/E 9.23) offset by margin pressures. Key opportunities include dividend yield and cost savings program, while risks involve declining profitability and competitive pressures. Wall Street consensus price target of $35.36 suggests limited upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →